Fresenius Kabi sells cancer compounding biz to NewCo Pharma

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacy

Fresenius sells oncology compounding unit to NewCo
Fresenius sells oncology compounding unit to NewCo
Fresenius Kabi has sold its cancer drug pharmacy network CFL GmbH to NewCo Pharma GmbH five years after spending €42m to buy compounding capacity in Germany.

The deal saw Mannheim-based NewCo Pharma GmbH take control of CRL, which specialises in the manufacture of patient specific preparations of injectable cancer treatments, including antibodies and cytostatics.

CFL has compounding centers in Aschaffenberg and Munich. It also has compounding pharmacies in Bonn (Compounding Rheinische), Mannheim (Fortuna Herstellung) Osnabruck, (Onco Service) and Stuttgart (cas central compounding baden-wuttemberg).

Fresnius spokesman Matthais Link confirmed the divestiture, telling “We announced the sale of the German oncology compounding business being closed yesterday evening​.”

He added that: “The deal includes all five compounding centres of CFL, the centre in Aschaffenburg [where the organisation is based] among them​.”


Fresenius Kabi, CFL’s parent division, acquired cas central compounding baden-wuttemberg and Fortuna Herstellung in 2010 for €31m​.

A year later it spent another €11m on compounding capacity​ in Germany.

The firm did not say what prompted it to divest CFL, which it said generated revenue of €77m ($87m) last year.

Link stressed that Fresnius will continue to operate in the compounding sector which – in Germany – will be focused on the production of intravenous nutrition products “because the company sees more attractive growth opportunities in this area. So we bundle our resources there​.”

Mannheim-based NewCo Pharma was founded on January 1 by pharmacist Michael Schill and also focuses on IV oncology drug compounding.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more